Lin et al.57 developed a HER2-targeted aptamer-modified DNA tetrahedral delivery system, by combining the erythrocyte membrane and pH-responsive liposomes through bionic camouflage technology to enhance the in vivo retention time and the tumor aggregation effect of HER2-positive cancer therapeutics. Here, ERBB2 is linked to neoplasm.